A B S T R A C T Monoclonal antibodies were prepared against pyruvate kinase (PyKi; ATP: pyruvate phosphotransferase, EC 2.7.1.40) and used to quantitate PyKi content in L2 lung cells and WI-38 fibroblasts cultivated under hypoxic and normoxic conditions. After 96 h of hypoxic cultivation, PyKi activity was significantly increased in both cell types (L2: normoxia [Po2 = 142 torr], 0.11+0.01 [SD]; hypoxia [Po2 = 14 torr], 0.25 ±0.04 U/,ug DNA, P < 0.01). PyKi content increased proportionately in both cell lines (L2: normoxia, 0.44 +0. 13; hypoxia, 0.94±0.13 ,g enzyme protein/,Lg DNA).
INTRODUCTION
Chronic 02 depletion is an important clinical problem, but the cellular mechanisms responsible for adaptation to chronic hypoxia are obscure. The increased rate of glycolysis following acute hypoxic exposure was first described by Pasteur. The Pasteur effect has since been demonstrated in a wide variety of tissues, and maximal response occurs rapidly after hypoxic exposure. It is' generally accepted that the Pasteur effect is related to acute increases in intracellular phosphofructokinase (PFK;' ATP: d-fructose 6-phosphate 1-phosphotransferase, EC 2.7.1.11) activity resulting from changes in the concentration of low molecular weight allosteric regulators, although other alterations in enzyme activities participate (1, 2) .
We have previously demonstrated that chronic hypoxic exposure of a variety of tissues and cell systems results in substantial additional increases in the rate of glycolysis beyond those produced by the Pasteur effect. The rate ofglycolysis in peritoneal macrophages (ambient Po2 chronically < 15 torr) is three times greater than in alveolar macrophages (ambient Po2 = 100 torr); when alveolar macrophages are maintained under hypoxic conditions in vitro for several days, their glycolytic capacity exceeds that of peritoneal macrophages (3) (4) (5) . This stimulation ofglycolysis by chronic hypoxic exposure may also explain the bioenergetic differences observed between pulmonary artery endothelial cells (Po2 = 40 torr) and aortic endothelial cells (Po2 = 100 torr), as well as the differences observed in fetal and neonatal brain (6, 7) . Increased activity of rate-limiting glycolytic enzymes has also been found in fibroblast, endothelial, and kidney cell lines cultured under hypoxic conditions. Therefore, the phenomenon appears to be a common cellular response to 02 depletion.
Two lines of evidence suggest that the stimulation of glycolysis by chronic hypoxic exposure operates by a mechanism distinct from the Pasteur effect. The increase in glycolysis following acute hypoxic exposure (Pasteur effect) occurs within minutes; the activity of PFK and pyruvate kinase (PyKi; ATP: pyruvate phosphotransferase, EC 2.7.1.40), two rate-limiting enzymes in glycolysis, are unchanged when assayed under conditions of substrate excess and in which low molecular weight regulators are present in constant amount. In contrast, the further increase in glycolysis seen after chronic hypoxic exposure is first demonstrable after 24 (9) , was maintained in RPMI-1640 containing 15% FCS, 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 )ug/ml streptomiiycin (coImlplete medium).
Enzyme assays. PyKi activity was measured by the assay of Valentine and Tanaka (10) . In studies using L2, 1 U of activity is defined as the amount of enzyme required to consume 1 ,umol NADH/min at 37°C. In studies using WI-38 fibroblasts, PyKi activity was measured at 22°C. PyKi isozymes were determined electrophoretically by the technique of Susor et al. (11) .
Development of monoclonal antibodies. Monoclonal antibodies were developed using a modification of the technique of Kohler and Milstein (9, 12, 13) . Three 6-wk-old BALB/c mice were immunized by intraperitoneal injection of 0.2 ml of water-in-oil suspension of complete Freund's adjuvant containing 1 mg of rabbit muscle PyKi. 3 wk later animals were boosted by intraperitoneal injection of 0.2 ml of phosphate-buffered saline (PBS) containing 0.025 mg rabbit muscle PyKi.
3 d after boosting, the mice were sacrificed, the spleens removed, and 1.6 x 108 spleenocytes fused with 0.4 x 108 NS-1 myeloma cells by gentle stirring in 1 ml polyethylene glycol-1500 as previously described (13) . Cells were plated in 96-well culture dishes and hybrid cells selected on the basis of growth in HAT medium (100 ,uM hypoxanthine, 0.4 ,tM aminopterin, and 16 ,uM thymidine in complete medium).
Detection of hybrids secreting antipyruvate kinase antibody. Anti-PyKi antibody secretion was assayed by solidphase radioimmunoassay on 96-well u-shaped microtiter plates (14) . 30 ,ul of a 0.1-mg/ml solution of rabbit muscle PyKi in PBS was pipeted into each well and allowed to stand at room temperature for 1 h. Wells were emptied and rinsed three times with 0.25 ml PBS containing 1% bovine serum albumin and 0.02% sodium azide (radioimmunoassay buffer). 20 ,ul of spent medium from individual primary culture wells was pipetted into each well of the microtiter plate and reacted at room temperature for 1 h. Unbound antibody was removed and each well rinsed three times with 0.25 ml of radioimmunoassay buffer. Finally, 20 ,ul of RPMI 1640 medium containing '251-labeled anti-mouse immunoglobulin (Ig) allotype antibodies (10,000 cpm each anti-Ig-la and anti-Ig-4a) (15) was added to each well and reacted for 1 h at room temperature. Unbound antibody was removed, and the wells rinsed three times with 0.25 ml of radioimmunoassay buffer. 1251 bound was determined by cutting out and counting each well in a Beckman 4000 gamma counter (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.). Wells corresponding to primary culture wells secreting anti-PyKi antibodies bound 1251 in excess of 5-10 times background (50-200 cpm).
Cloning of antibody-producing cells. Contents of wells in the primary culture that produced anti-PyKi antibodies were transferred to 24-well tissue culture plates in final volume of 1 ml complete medium containing 5 x 106 thymocyte feeder cells. After 7-10 d growth in 24-well plates, cells were clonied using a fluorescence-activated cell sorter (FACS-II) (16) . A single, large, viable cell from each culture was dispensed into each well of a 96-well culture plate containing 0.1 ml complete medium and 1 x 106 thymocytes. Cultures were maintained in log-phase growth (0.5-2 x 101 cells/ml) and expanded by transferring se(luentially into 24-well tissue culture plates (2 ml), T-25 flasks (5 ml), and finally T-75 flasks (20-50 ml).
Preparation ofa ntibodiesfor radioim mu noassaty. Purified monoclonal anti-Ig-la and anti-Ig-4a were iodinated by a modification of the procedure of Fraker and Speck (17) . AntiPyKi monoclonal antibody was titered by using serial 1:2 dilutions of antibody (usually spent medium from cloned hybrid cells) in the solid-phase radioimmunoassay described below. A dilution of antibody resulting in 60-80% maximiial binding of '251-anti-Ig-4a was used for quantitationi of PyKi by radioimmunoassay (1:2 to 1:32 dilution for spent mediumii).
Enzynme Adaptation to Chrontic HypoXia
Preparation of solid-phase antibody. 5 mg of purified monoclonal antibody was dialyzed against 3 mM potassium phosphate buffer (pH 6.3) and coupled to 100 mg of < 10-,um diameter acrylamide beads (Immunobeads, Bio-Rad Laboratories, Richmond, Calif.) using 1-ethyl-3 (3-dimethylaminopropyl) carbodiimide HCl (EDAC) according to the instructions provided by the manufacturer. The beads were washed extensively with PBS, 5 M guanidine-HCl in PBS (pH 7.2), and again in PBS, then resuspended in PBS at 10 mg beads/ml and stored at 40C.
Quantitation of PyKi activity and content. PyKi in L2 was quantitated by a consumption radioimmunoassay. Confluent plates of cells were incubated under Po2 14 torr/Pco2 36 torr (hypoxia) or Po2 142 torr/Pco2 36 torr (normoxia) for 4 d.
For experiments on WI-38 fibroblasts, cells were trypsinized, plated at 500,000 cells/100-mm petri dish, and incubated under air/5% CO2 for 2 d. Cells were then exposed to normoxia or hypoxia as described above for 96 h.
Cells were rinsed with 10 ml PBS and detached with a rubber policeman, and contents of the plates transferred to a test tube in a final volume of 1.0 ml. Contents were sonicated (Branson Sonicator, Branson Sonic Power Co., Danbury, Conn.; micro-tip; power setting = 3; 10 s) and centrifuged (10,000 g; 30 min). Aliquots of sonicate were assayed for DNA content (18) . A 50-,ul aliquot of the supernate was assayed for PyKi activity. No detectable PyKi activity was found in the pellet of cells cultivated under normoxic or hypoxic conditions, indicating that all PyKi activity was extracted and present in the supernate. To determine PyKi content, a series of 1:2 dilutions of supernate in RPMI-1640 between undiluted and 1:128 dilution was prepared. Rabbit muscle PyKi was used as a standard. A 25-Ag/ml solution in PBS was prepared (concentration was determined spectrophotometrically) (19) , and serial dilutions in RPMI-1640 containing 0.20-25 gg/ml were also prepared. 20-,ul aliquots of serially diluted standard solutions or cell supemates were added to 20 Al of an appropriately diluted solution (see above) of anti-PyKi antibody (6B-H12) in a coated microtiter plate and incubated at 40C overnight. Residual unbound antibody was assayed as described above. A standard curve was prepared (Fig. 2) (1, 050 Ci/mmol) for 15 h. Cells were rinsed, harvested in 0.5 ml PBS, sonicated, and centrifuged (10,000 g; 20 min).
100 ,ul of a solution containing 50 ,ug/ml anti-PyKi antibody (6B-H12) and 50 g/mrnl BSA in PBS was placed in a well of a microtiter plate and allowed to stand at room temperature for 1 h (15). The solution was removed, and the well rinsed five times with 0.25 ml RIA buffer; 50 gl labeled cell supernate was added, and the solution allowed to stand for 1 h. Unbound radioactivity was removed by washing the well five times with radioimmunoassay buffer containing 0.3 M NaCl; the contents of the well (absorbed antibody and immunoprecipitated, labeled protein) were solubilized in 60 ul of 0.0625 M Tris-HCl (pH 6.8) containing 2% sodium dodecyl sulfate (SDS) and 2% ,&mercaptoethanol, and boiled for 1 min. SDSacrylamide gel electrophoresis was performed using the system of Laemmli (20) in 90 x 1.5-mm resolving slab gels (10% acrylamide/0.27% hisacrylamide), and fluorograms prepared by the method of Bonner and Laskey (21 
RESULTS
Production of anti-PyKi antibodies. Two cell-fusion experiments were performed on spleen cells obtained from three mice; six 96-well plates were plated and cells subjected to hypoxanthine:aminopterin:thymidine medium selection. When tested after 3 wk of growth, medium from 11/576 cells was found to contain anti-PyKi antibody. All positive wells were producing a yGl(Ig-4a) antibody type. Cells in each positive well were transferred to 24-well tissue culture plates, and after an additional week of growth, single, viable cells from each culture were cloned into 96-well tissue culture plates. When the cloning plates showed vigorous growth, clones were tested for anti-PyKi antibody production. In 8 of 11 cloning plates, 3-24 ofthe 96 clones were producing anti-PyKi antibody. Selected clones from each plate were expanded, and anti-PyKi antibody produced from these cell lines were used in the experiments described below. No anti-PyKi antibody-producing clones were obtained from three of our positive primary wells, and these cell lines were discarded.
Specificity of anti-PyKi monoclonal atitibodies. To demonstrate that the anti-PyKi antibody (6B-H 12) used was capable of reacting with all cellular PyKi, the following studies were performed. L2 were homogenized, centrifuged at 10,000 g, and the supernate assayed for PyKi activity. Preincubation of aliquots of this supernate with increasing amounts (0.5-2 mg) of acrylamide beads covalently linked to anti-PyKi monoclonal antibody resulted in a progressive decrease of PyKi activity remaining in the supernate. Addition of excess beads (4 mg) completely eliminated PyKi activity in the s upernate.
Labeled proteins immunoprecipitated from supernates of L2 by anti-PyKi antibody (6B-H 12) were examined by SDS-acrylamide gel electrophoresis (Fig. 1) . Greater than 95% of immunoprecipitated radioactivity migrated as a single sharp band with mobility identical Fig. 2 . A fixed amount of antibody was preincubated with increasing amounts of rabbit muscle PyKi or supemate from L2, and residual anti-PyKi antibody was then assayed by solid-phase radioimmunoassay. Preincubation of antibody with 20 ng (0.0004 U) of rabbit muscle PyKi resulted in a 50% reduction in residual antibody activity; the linear portion of the standard curve ranged from 10 to 100 ng of PyKi.
The consumption of anti-PyKi antibody by PyKi present in supernates from L2 closely paralleled that produced by an equal amount of rabbit muscle PyKi enzyme activity (Fig. 2) , although the curve is shifted slightly to the right (see below). These data also indicate that anti-PyKi antibody (6B-H 12) has high specificity for PyKi. Ifsupernates from L2 (4) (Fig. 3) . Electrophoretic analysis demonstrated that both hypoxically and normoxically cultivated L2 contained only the M2 isozyme of PyKi (data not shown).
PyKi content determined by consumption radioimmunoassay was also more than twice as high in hypoxically cultivated cells than in cells grown under normoxic conditions (0.94±0. 13 [SD] and 0.44±0.01 ,g enzyme protein/,ug DNA, respectively; P < 0.01). Because the activity and content increased proportionately, the specific activity of the PyKi in L2 under the conditions of our assay was similar in normoxicand hypoxic-exposed cells (261±11 and 261±14 U/mg enzyme protein, respectively; P not significant). Further, the specific activity of PyKi in L2 was similar to the specific activity of rabbit muscle standard (214 U/mg enzyme protein).
Effects of hypoxic exposure on PyKi activity and content in WI-38 human lungfibroblasts. In similar experiments, WI-38 fibroblasts were exposed to Po2 142 torr/Pco2 36 torr or Po2 14 torr/Pco2 36 torr for 96 h, and measurements of PyKi activity, content, and specific activity were made as described above. Hypoxic cultivation resulted in a twofold increase in PyKi activity compared with air-grown cells (0.147±0.019 and 0.079±0.002 U/,g DNA, respectively; P < 0.01). Enzyme content increased proportionately (hypoxic cultivation, 2.97±0.30 ,tg PyKi/,ug DNA; normoxic cultivation, 1 We used purified rabbit muscle PyKi as the antigen. This form of PyKi is the M1 isozyme and thus is different from the M2 PyKi found in the cell types studied. As a result, our estimates of content are in error by the differences in mass between the two purified enzymes. Other workers have reported molecular masses for both Ml and M2 isozymes of 210,000-250,000 daltons (19, (24) (25) (26) (27) . Rabbit muscle PyKi and PyKi precipitated from supernates of L2 by antibody covalently linked to acrylamide beads had identical mobility when examined by SDS-polyacrylamide gel electrophoresis; therefore, errors resulting from differences in molecular mass must be quite small.
In addition, if the affinity of our antibody for rabbit muscle PyKi and cellular PyKi differed, a systematic error would be introduced. As mentioned earlier, the consumption of antibody by equal activity of the two PyKi types was similar; however, the curve for L2 PyKi was shifted slightly to the right (Fig. 2) . This finding is consistent with the interpretation that our antibody had a higher affinity for rabbit muscle PyKi (the original antigen) than for L2 PyKi. A more likely explanation is that the extensive purification procedure used for isolation of rabbit muscle PyKi resulted in inactivation of a fraction of enzyme that retained antigenic properties. In experiments quantitating PyKi content, therefore, we used a standard curve based on absorbance of a rabbit muscle PyKi solution, which would more closely reflect total enzyme present. The apparent specific activity of L2 PyKi determined by this assay (261 U/mg enzyme) was higher than that of rabbit muscle PyKi and similar to values reported by other workers. These considerations would not influence conclusions regarding the relative content of PyKi in hypoxic and normoxic cells, since affinity of PyKi for antibody was not influenced by hypoxic exposure.
We have not studied whether the increase in enzyme content is related to increased biosynthesis or decreased biodegradation, or have we studied the problem of how such alterations are produced by changes in 02 availability. Both problems can be approached by using monoclonal antibodies.
The potential usefulness of monoclonal antibodies directed against enzymes has been indicated by Milstein (28) . There are several advantages of monoclonal antibodies when compared with polyvalent antibody preparations conventionally employed in studies ofthis type. The specificity of the antibodies obtained (probably detecting a single antigenic determinant) is not dependent upon the purity of the antigen used for immunization, and therefore extensive purification of enzyme is not necessary for antibody production. Similarly, the need for absorption ofantisera is obviated. The antibody can be produced in almost unlimited (quantity, and cell lines or antibody can be made available to other workers.2
Despite these limitations, it is clear that chronic hypoxia regulates the rate of glycolysis by direct alteration ofenzyme content. It appears likely that this mechanism is not only present in cell culture systems, but is a major determinant of the rate of glycolysis in a variety of in vivo systems as well.
